Lilly Pulitzer’s treasured Sunshine Sale is back with splurge-worthy discounts and new styles perfect for the winter or ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...

It won the Pulitzer Prize in 2020. Now comes a film version of the book, directed and written (with Joslyn Barnes) by Ross, whose only previous feature is the luminous 2018 documentary “Hale ...

Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation.

Join us as we take a look at some of the most glamorous celebrities in swimsuits over the winter break… JLo spent Christmas and New Year in Aspen, but that didn't stop her from slipping into a ...

In the time since, though, some analysts have said the reaction is overblown, particularly for weight-loss drugmakers like Wegovy, and Ozempic maker Novo Nordisk and Zepbound maker Eli Lilly.

Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

whose investigation into Cambridge Analytica earned her a nomination for the Pulitzer Prize in 2019. The journalist is also well known for her long-running legal row with Brexit campaigner Arron ...

Shelby Knowles / Bloomberg / Getty Images Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker ...